The biotech M&A machine is running hot. argenx SE (NASDAQ: ARGX) announced a definitive all-cash agreement to acquire clinical-stage biotech Forte Biosciences (NASDAQ: FBRX) at $77 per share — a deal that values the company at over $2.2 billion. The offer represents a 40% premium to Forte’s pre-announcement closing price, and an even more striking 86% premium to the stock’s volume-weighted average price following its successful Phase 1b clinical readout on July 9. FBRX shares exploded on the news, and the deal is the latest sign that well-capitalized immunology companies are aggressively hunting for pipeline assets to offset looming patent expirations.
The target asset is Forte’s FB102, a first-in-class anti-CD122 antibody that showed compelling efficacy in vitiligo — a skin depigmentation condition affecting 1-2% of the global population with no widely approved cure. In a 24-week clinical trial, FB102 delivered a 29.6% mean improvement on the Facial Vitiligo Area Scoring Index, separating from placebo as early as day 64. The drug also has early data in celiac disease, giving argenx a potential multi-indication asset from a single acquisition. For argenx, the strategic rationale is clear: its core product Vyvgart — a blockbuster FcRn-blocker — just posted its 17th consecutive quarter of growth and drove Q1 2026 net sales of $1.3 billion, up 63% year-over-year. But near-total reliance on one product is a structural risk. CEO Karen Massey’s “Vision 2030” framework explicitly targets 10 designated indications and 50,000 patients globally. argenx funded the deal from a $4.9 billion cash position — making $2.2 billion an achievable move without diluting shareholders.
The broader context matters for any investor following pharma and biotech: the industry is staring down a $300 billion patent cliff in the second half of this decade, and large-cap companies are deploying cash aggressively to fill pipeline gaps. The Inflation Reduction Act’s pricing mechanics have also shifted buyer preferences toward large-molecule biologics over small-molecule drugs — exactly the category FB102 falls into — giving deals like this one a structural tailwind beyond just argenx’s specific needs. For retail investors, this story cuts two ways. FBRX shareholders who held through the uncertainty were handsomely rewarded — an 86% pop in weeks. ARGX investors will want to see Phase 2 clinical milestones from FB102 and a clear path to regulatory submission to validate the $2.2 billion price tag. Biotech M&A remains one of the most reliable sources of outsized short-term gains in the market, and acquisitions of this size signal that immunology and rare disease are where the big money is hunting right now.
